Pancragen — EU research guide.
Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) from the Khavinson bioregulator series proposed to support beta-cell differentiation and pancreatic tissue gene regulation. It is studied in the same general research context as Suprefort, another pancreas-targeted bioregulator in the same family.
What is Pancragen?
Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) from the Khavinson bioregulator series proposed to support beta-cell differentiation and pancreatic tissue gene regulation. It is studied in the same general research context as Suprefort, another pancreas-targeted bioregulator in the same family.
What does the research show?
Available research centers on beta-cell and insulin-regulation markers in animal models from Eastern European groups. No independently replicated human trial data is publicly available as of mid-2026, and the proposed mechanism remains far less characterized than established metabolic peptides like GLP-1 analogues.
EU legal status
Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory metabolic research only.
Molecular information
Pharmacokinetics
Pancragen is not yet in our price comparison
We expand EU supplier coverage every month.